XTL Biopharmaceuticals Ltd: Form 20-F for the period ended Dec 31, 2021
Filed with the SEC on Mar 30, 2022 and accepted by EDGAR at Mar 30, 2022, 21:13 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2021-01-01 to 2021-12-31 | −$1.0m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months2021-01-01 to 2021-12-31 | $435.0k | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | $0.00 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | $0.00 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$1.0m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2021-12-31 | $3.0m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2021-12-31 | $6.2m | ifrs-full:CurrentAssets |
| Total assets | At period end2021-12-31 | $6.6m | ifrs-full:Assets |
| Shareholders' equity | At period end2021-12-31 | $5.3m | ifrs-full:Equity |
| Shares outstanding | At period end2021-12-31 | 544,906,149 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-22-016244. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.